ADAMTS-13 Levels Do Not Predict Outcome in Thrombotic Thrombocytopenic Purpura: Protein S Levels Are Maintained during Plasma Exchange with Solvent Detergent Treated Plasma

Introduction The ultimate therapy for TTP is not yet defined. While approximately 85% of patients respond to plasma exchange with FFP, the use of alternative solutions such as cryosupernatant plasma, which is deficient in the high molecular weight forms of vWF. has not been proven by appropriate ran...

Full description

Saved in:
Bibliographic Details
Published inBlood Vol. 110; no. 11; p. 2895
Main Authors Rock, Gail A., Anderson, David, Benny, Barrett, Barth, David, Clark, William, Foley, Ronan, Sutton, David, Leblond, Pierre
Format Journal Article
LanguageEnglish
Published Elsevier Inc 16.11.2007
Online AccessGet full text

Cover

Loading…
Abstract Introduction The ultimate therapy for TTP is not yet defined. While approximately 85% of patients respond to plasma exchange with FFP, the use of alternative solutions such as cryosupernatant plasma, which is deficient in the high molecular weight forms of vWF. has not been proven by appropriate randomized prospective sample trials. However, it is intellectually appealing. Additionally, the use of the ADAMTS 13 level either to predict disease or outcome has not been resolved. Methods Cryosupernatant plasma (CSP) was compared to solvent detergent treated plasma (SDP) over one cycle (nine days) of plasma exchange (PE) and subsequent procedures as required. Throughout treatment, ADAMTS 13 and protein S levels were followed. Results At the primary end point of one month, 3 of 35 of the CSP and 1 of 27 of the SDP patients died. The average platelet count was 184 × 109 per litre for CSP and 209 × 109 per litre for SDP. While vWF and FVIII were elevated in all patients at entry, no unusually large vWF multimers were seen at any time. At entry 9 patients had ≤ 0–10% ADAMTS 13 and 14 of 62 had normal levels with the rest in between. At presentation only 9 patients had 100% inhibitor activity with no inhibitor in 18 patients. Of the four patients who died, two who received CSP, had 100% enzyme activity at presentation whereas one had no ADAMTS-13 and another had 10%. All 4 patients died within 10 days. Fifteen patients with less than 10% enzyme activity had >1.5 vWF. However, elevated (>3u/mL) vWF was seen in the presence of normal ADAMTS-13 levels. Six months after remission, and in the presence of a normal platelet count, ADAMTS13 remained low in 5 patients and normal in 15.Protein S levels in 41/62 patients studied showed little variation during therapy with values on day 3 and 5, similar to those seen on entry. Conclusion In idiopathic TTP, ADAMTS 13 levels do not correlate with disease, and are not predictive of outcome. While protein S levels in the SDP were lower than those found in FFP, this did not appear to have clinical significance.
AbstractList Introduction The ultimate therapy for TTP is not yet defined. While approximately 85% of patients respond to plasma exchange with FFP, the use of alternative solutions such as cryosupernatant plasma, which is deficient in the high molecular weight forms of vWF. has not been proven by appropriate randomized prospective sample trials. However, it is intellectually appealing. Additionally, the use of the ADAMTS 13 level either to predict disease or outcome has not been resolved. Methods Cryosupernatant plasma (CSP) was compared to solvent detergent treated plasma (SDP) over one cycle (nine days) of plasma exchange (PE) and subsequent procedures as required. Throughout treatment, ADAMTS 13 and protein S levels were followed. Results At the primary end point of one month, 3 of 35 of the CSP and 1 of 27 of the SDP patients died. The average platelet count was 184 × 109 per litre for CSP and 209 × 109 per litre for SDP. While vWF and FVIII were elevated in all patients at entry, no unusually large vWF multimers were seen at any time. At entry 9 patients had ≤ 0–10% ADAMTS 13 and 14 of 62 had normal levels with the rest in between. At presentation only 9 patients had 100% inhibitor activity with no inhibitor in 18 patients. Of the four patients who died, two who received CSP, had 100% enzyme activity at presentation whereas one had no ADAMTS-13 and another had 10%. All 4 patients died within 10 days. Fifteen patients with less than 10% enzyme activity had >1.5 vWF. However, elevated (>3u/mL) vWF was seen in the presence of normal ADAMTS-13 levels. Six months after remission, and in the presence of a normal platelet count, ADAMTS13 remained low in 5 patients and normal in 15.Protein S levels in 41/62 patients studied showed little variation during therapy with values on day 3 and 5, similar to those seen on entry. Conclusion In idiopathic TTP, ADAMTS 13 levels do not correlate with disease, and are not predictive of outcome. While protein S levels in the SDP were lower than those found in FFP, this did not appear to have clinical significance.
Abstract Introduction The ultimate therapy for TTP is not yet defined. While approximately 85% of patients respond to plasma exchange with FFP, the use of alternative solutions such as cryosupernatant plasma, which is deficient in the high molecular weight forms of vWF. has not been proven by appropriate randomized prospective sample trials. However, it is intellectually appealing. Additionally, the use of the ADAMTS 13 level either to predict disease or outcome has not been resolved. Methods Cryosupernatant plasma (CSP) was compared to solvent detergent treated plasma (SDP) over one cycle (nine days) of plasma exchange (PE) and subsequent procedures as required. Throughout treatment, ADAMTS 13 and protein S levels were followed. Results At the primary end point of one month, 3 of 35 of the CSP and 1 of 27 of the SDP patients died. The average platelet count was 184 × 109 per litre for CSP and 209 × 109 per litre for SDP. While vWF and FVIII were elevated in all patients at entry, no unusually large vWF multimers were seen at any time. At entry 9 patients had ≤ 0–10% ADAMTS 13 and 14 of 62 had normal levels with the rest in between. At presentation only 9 patients had 100% inhibitor activity with no inhibitor in 18 patients. Of the four patients who died, two who received CSP, had 100% enzyme activity at presentation whereas one had no ADAMTS-13 and another had 10%. All 4 patients died within 10 days. Fifteen patients with less than 10% enzyme activity had >1.5 vWF. However, elevated (>3u/mL) vWF was seen in the presence of normal ADAMTS-13 levels. Six months after remission, and in the presence of a normal platelet count, ADAMTS13 remained low in 5 patients and normal in 15.Protein S levels in 41/62 patients studied showed little variation during therapy with values on day 3 and 5, similar to those seen on entry. Conclusion In idiopathic TTP, ADAMTS 13 levels do not correlate with disease, and are not predictive of outcome. While protein S levels in the SDP were lower than those found in FFP, this did not appear to have clinical significance.
Author Anderson, David
Rock, Gail A.
Sutton, David
Barth, David
Foley, Ronan
Leblond, Pierre
Benny, Barrett
Clark, William
Author_xml – sequence: 1
  givenname: Gail A.
  surname: Rock
  fullname: Rock, Gail A.
  organization: Canadian Apheresis Group, Ottawa, ON, Canada
– sequence: 2
  givenname: David
  surname: Anderson
  fullname: Anderson, David
  organization: Queen Elizabeth II HSC, Halifax, NS, Canada
– sequence: 3
  givenname: Barrett
  surname: Benny
  fullname: Benny, Barrett
  organization: Vancouver General Hospital, Vancouver, BC, Canada
– sequence: 4
  givenname: David
  surname: Barth
  fullname: Barth, David
  organization: Princess Margaret Hospital, Toronto, ON, Canada
– sequence: 5
  givenname: William
  surname: Clark
  fullname: Clark, William
  organization: London Health Science Center, London, ON, Canada
– sequence: 6
  givenname: Ronan
  surname: Foley
  fullname: Foley, Ronan
  organization: Henderson General Hospital, Hamilton, ON, Canada
– sequence: 7
  givenname: David
  surname: Sutton
  fullname: Sutton, David
  organization: Princess Margaret Hospital, Toronto, ON, Canada
– sequence: 8
  givenname: Pierre
  surname: Leblond
  fullname: Leblond, Pierre
  organization: Hopital de l'Enfant Jesus, Quebec City, QC, Canada
BookMark eNqFkNlOAjEUhhuDiYA-g32BwS7M5t0EcElASEBvJ6U9AzVDSzoF5Z18SAvItRdnzfn_5Hwd1DLWAEL3lPQozdjDsrZW9T7oae6xLI9P6Qq1acyyiBBGWqhNCEmifp7SG9Rpmk9CaJ-zuI1-imExWcwjyvEY9lA3eGjxm_V45kBp6fF056XdANYGL9bObpbWa3lp5cHbLZiwmO3cdufEY9BZD-F4fvErHOCJ0MaHAIXVzmmzwrNaNBuBR99yLcwK8Jf2azy39R6Mx0Pw4FbHbuFA-KA6n9-i60rUDdz91S56fxotBi_RePr8OijGkaQkiSMhklRxkfNMZP1UEUpjqpZAmEokYxyqPE6rVKksqShf5pwRSLjq0zhNmBIq512Unn2ls03joCq3Tm-EO5SUlEfo5Ql6eYQe5vLI-5SCsjgrw-ew1-DKRmowMrB0IH2prP7X4xcKT5Cm
ContentType Journal Article
Copyright 2007 American Society of Hematology
Copyright_xml – notice: 2007 American Society of Hematology
DBID 6I.
AAFTH
AAYXX
CITATION
DOI 10.1182/blood.V110.11.2895.2895
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
DatabaseTitle CrossRef
DatabaseTitleList
CrossRef
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Biology
Anatomy & Physiology
EISSN 1528-0020
EndPage 2895
ExternalDocumentID 10_1182_blood_V110_11_2895_2895
S0006497119891449
GroupedDBID ---
-~X
.55
1CY
23N
2WC
34G
39C
4.4
53G
5GY
5RE
5VS
6I.
6J9
9M8
AAEDW
AAFTH
AAXUO
ABOCM
ABVKL
ACGFO
ADBBV
AENEX
AFFNX
AFOSN
AHPSJ
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BTFSW
C1A
CS3
DIK
DU5
E3Z
EBS
EJD
EX3
F5P
FDB
FRP
GS5
GX1
IH2
J5H
K-O
KQ8
L7B
LSO
MJL
N4W
N9A
OK1
P2P
R.V
RHF
RHI
ROL
SJN
THE
TR2
TWZ
W2D
W8F
WH7
WOQ
WOW
X7M
YHG
YKV
ZA5
ZGI
0R~
0SF
AALRI
AAYXX
ADVLN
AITUG
AKRWK
AMRAJ
CITATION
H13
ID FETCH-LOGICAL-c1065-aa67d3a938a847d01151dbe02d6c223ef957f7dd86f13b9320e63d415762dad93
IEDL.DBID ABVKL
ISSN 0006-4971
IngestDate Fri Aug 23 00:41:19 EDT 2024
Fri Feb 23 02:43:52 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Language English
License This article is made available under the Elsevier license.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c1065-aa67d3a938a847d01151dbe02d6c223ef957f7dd86f13b9320e63d415762dad93
OpenAccessLink https://www.sciencedirect.com/science/article/pii/S0006497119891449
PageCount 1
ParticipantIDs crossref_primary_10_1182_blood_V110_11_2895_2895
elsevier_sciencedirect_doi_10_1182_blood_V110_11_2895_2895
PublicationCentury 2000
PublicationDate 2007-11-16
PublicationDateYYYYMMDD 2007-11-16
PublicationDate_xml – month: 11
  year: 2007
  text: 2007-11-16
  day: 16
PublicationDecade 2000
PublicationTitle Blood
PublicationYear 2007
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
SSID ssj0014325
Score 1.906931
Snippet Introduction The ultimate therapy for TTP is not yet defined. While approximately 85% of patients respond to plasma exchange with FFP, the use of alternative...
Abstract Introduction The ultimate therapy for TTP is not yet defined. While approximately 85% of patients respond to plasma exchange with FFP, the use of...
SourceID crossref
elsevier
SourceType Aggregation Database
Publisher
StartPage 2895
Title ADAMTS-13 Levels Do Not Predict Outcome in Thrombotic Thrombocytopenic Purpura: Protein S Levels Are Maintained during Plasma Exchange with Solvent Detergent Treated Plasma
URI https://dx.doi.org/10.1182/blood.V110.11.2895.2895
Volume 110
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT9wwEB5REG0vVbtQQR9oDhW3sHk6CbewC6KFhZV2QdwiO_aqK7EJSrNS-U_9kZ1xElSkSj30YsWRJ4k8jucb-xsPwBfpizhUgo--jF0nTFzpqCgNnVBwmnIVewu7Yzq5Euc34be76G4DRn0sDNMqu7m_ndPtbN3dGXa9OXxYLjnGl8xpGnvM-iG3IH0BWz6hX_o7t7KT24vLp82EMPDbRAbkPLNAR_MiZD207PCjW8_Wj8j5iGzxdyP1h-E5ewtvOsSIWftR72DDlAPYyUryllePeIiWw2kXxwewfdJfvRr1mdwG8HLSbaDvwK9snE3mM8cL8JLpQj9wXOFV1eC05jYNXq8b6gqDyxLn3-tqpSp6bX9ZPDacbYtuTEk_61oek1zF-TJx1j8vqw1O5LLkJQejsQ2DxCmB9JXE059toDHy8i_OqntmW-KYKTkc4oVzhrAk1TbfhZuz0_no3OkSNjgFeZaRI6WIdSDTIJFk9DSjTU8r4_paFARDzCKN4kWsdSIWXqAIObpGBJogBM3IWuo0eA-bZVWaPcAoJeQgImOSQoVKaSXImhdaRGnhalLzPri9hvKH9lyO3PoziZ9bpeasVKrnrE9b7MNxr8n82RDLyXr8S_jD_wh_hNd2SZjZg-ITbDb12nwmLNOog26sHhCa_3rxG9qY8VI
link.rule.ids 315,783,787,27581,27936,27937,45675
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELdGJ9heEHRMbHzdA-Ita77sNHvL2k2FNaVSs2lvkR27ohJNppBK7H_ij-TOSRBISDzwEtmWL4l8lu939u98jL2XvohCJejqy8h1wrErHcXj0AkFpSlXkbe2J6bpQsxuwk93_G6PTfpYGKJVdmt_u6bb1bprGXWjObrfbCjGF81pHHnE-kG3IH7E9hENRHzA9pOL2-v5r8OEMPDbRAboPJNAR_NCZD2y7PCzW8_Wz9D54PbxdyP1m-G5esaedogRkvannrM9Uw7ZUVKit7x9gA9gOZx2c3zIHl_0pYNJn8ltyJ6k3QH6EfuRTJM0WzleAHOiC32DaQWLqoFlTX0a-LxrcCgMbErIvtTVVlX42b5YPDSUbQsblqifXS3PUa6ifJmw6t-X1AZSuSlpy8FoaMMgYYkgfSvh8nsbaAy0_Qur6iuxLWFKlBwK8YKMICxKtd1fsJury2wyc7qEDU6BniV3pBSRDmQcjCUaPU1o09PKuL4WBcIQs455tI60Hou1FyhEjq4RgUYIgSuyljoOjtmgrErzkgGPETkIbsy4UKFSWgm05oUWPC5c7Uf8hLm9hvL79l6O3PozYz-3Ss1JqVjPSZ_2ccLOe03mf0yxHK3Hv4RP_0f4HTuYZek8n39cXL9ih3Z7mJiE4jUbNPXOvEFc06i33bz9CaUs80c
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=ADAMTS-13+Levels+Do+Not+Predict+Outcome+in+Thrombotic+Thrombocytopenic+Purpura%3A+Protein+S+Levels+Are+Maintained+during+Plasma+Exchange+with+Solvent+Detergent+Treated+Plasma&rft.jtitle=Blood&rft.au=Rock%2C+Gail+A.&rft.au=Anderson%2C+David&rft.au=Benny%2C+Barrett&rft.au=Barth%2C+David&rft.date=2007-11-16&rft.pub=Elsevier+Inc&rft.issn=0006-4971&rft.eissn=1528-0020&rft.volume=110&rft.issue=11&rft.spage=2895&rft.epage=2895&rft_id=info:doi/10.1182%2Fblood.V110.11.2895.2895&rft.externalDocID=S0006497119891449
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-4971&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-4971&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-4971&client=summon